Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Muser

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|February 8, 2023
Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumabMaryia Zhdanava, Zhijie Ding, Ameur M Manceur, et al.
Advances in Therapy|March 21, 2020
Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United StatesCamilo Obando, Zhijie Ding, Erik Muser, et al.
Journal of Medical Economics|November 16, 2010
Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid populationEmily Durden, Erin Bagalman, Erik Muser, et al.
Clinical Therapeutics|June 24, 2017
Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance AbusePatrick Lefebvre, Erik Muser, Kruti Joshi, et al.
Journal of Medical Economics|July 2, 2020
Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costsAmeur M Manceur, Zhijie Ding, Erik Muser, et al.
Current Medical Research and Opinion|May 20, 2020
Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States populationDominic Pilon, Zhijie Ding, Erik Muser, et al.
Urologic Oncology|April 15, 2023
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamideBenjamin Lowentritt, Dominic Pilon, Ibrahim Khilfeh, et al.
Journal of Medical Economics|January 11, 2024
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiationDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.
Current Medical Research and Opinion|January 12, 2016
Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychoticsYongling Xiao, Erik Muser, Dong-Jing Fu, et al.
Future Oncology (London, England)|June 11, 2024
Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamideBenjamin H Lowentritt, Shawn Du, Carmine Rossi, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|February 8, 2023
Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumabMaryia Zhdanava, Zhijie Ding, Ameur M Manceur, et al.
Advances in Therapy|March 21, 2020
Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United StatesCamilo Obando, Zhijie Ding, Erik Muser, et al.
Journal of Medical Economics|November 16, 2010
Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid populationEmily Durden, Erin Bagalman, Erik Muser, et al.
Clinical Therapeutics|June 24, 2017
Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance AbusePatrick Lefebvre, Erik Muser, Kruti Joshi, et al.
Journal of Medical Economics|July 2, 2020
Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costsAmeur M Manceur, Zhijie Ding, Erik Muser, et al.
Current Medical Research and Opinion|May 20, 2020
Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States populationDominic Pilon, Zhijie Ding, Erik Muser, et al.
Urologic Oncology|April 15, 2023
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamideBenjamin Lowentritt, Dominic Pilon, Ibrahim Khilfeh, et al.
Journal of Medical Economics|January 11, 2024
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiationDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.
Current Medical Research and Opinion|January 12, 2016
Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychoticsYongling Xiao, Erik Muser, Dong-Jing Fu, et al.
Future Oncology (London, England)|June 11, 2024
Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamideBenjamin H Lowentritt, Shawn Du, Carmine Rossi, et al.
Pageof 5